NeuroPace (NASDAQ:NPCE – Get Free Report) was downgraded by research analysts at Wolfe Research from a “strong-buy” rating to a “hold” rating in a report released on Monday, Zacks reports.
A number of other equities research analysts have also recently issued reports on NPCE. Raymond James Financial set a $21.00 price objective on NeuroPace in a report on Tuesday, September 15th. KeyCorp lowered their target price on NeuroPace from $18.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday. Mizuho dropped their price target on NeuroPace from $22.00 to $12.00 and set an “outperform” rating for the company in a report on Monday. JPMorgan Chase & Co. downgraded NeuroPace from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $20.00 to $9.00 in a research note on Friday. Finally, Wells Fargo & Company downgraded NeuroPace from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $19.00 to $9.00 in a research note on Friday. Five investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, NeuroPace has an average rating of “Hold” and a consensus price target of $13.11.
Read Our Latest Analysis on NeuroPace
NeuroPace Stock Up 5.4%
Shares of NPCE opened at $7.97 on Monday. NeuroPace has a 52 week low of $5.46 and a 52 week high of $19.60. The firm has a market cap of $273.53 million, a P/E ratio of -14.23 and a beta of 1.98. The firm’s 50-day simple moving average is $13.07 and its 200 day simple moving average is $14.71. The company has a debt-to-equity ratio of 4.97, a quick ratio of 3.91 and a current ratio of 4.94.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Soleus Capital Management L.P. raised its stake in NeuroPace by 10.5% during the third quarter. Soleus Capital Management L.P. now owns 3,218,000 shares of the company’s stock worth $44,280,000 after acquiring an additional 306,878 shares in the last quarter. First Light Asset Management LLC lifted its holdings in shares of NeuroPace by 16.3% in the second quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company’s stock worth $45,464,000 after acquiring an additional 401,201 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of NeuroPace in the 2nd quarter valued at approximately $39,369,000. Deutsche Bank AG acquired a new stake in shares of NeuroPace in the 2nd quarter valued at approximately $14,919,000. Finally, Algert Global LLC boosted its stake in shares of NeuroPace by 2.9% in the 2nd quarter. Algert Global LLC now owns 184,774 shares of the company’s stock valued at $2,936,000 after purchasing an additional 5,218 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.
NeuroPace Company Profile
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
Further Reading
- Five stocks we like better than NeuroPace
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.
